Machiraju, P., Wang, X., Sabouny, R., Huang, J., Zhao, T., Iqbal, F., King, M., Prasher, D., Lodha, A., Jimenez-Tellez, N., Ravandi, A., Argiropoulos, B., Sinasac, D., Khan, A., Shutt, T
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
doi: 10.1210/jcem.75.2.1379256 82 U.S
Visual outcomes of traumatic lens dislocations and subluxations managed by pars plana vitrectomy and lensectomy
A philosophy of advanced clinical skill and artistry Natural results are not accidental
McDonald and her colleagues have designed a trial the Integrated Strategies for Breast Cancer Prevention and Interception in Elevated-Risk Women, or INSPIRE Study "to show that the drugs are actually causal for protection" against breast cancer, she says